top of page

EMA accepts to review Mylan and Biocon’s cancer biosimilar

The European Medicines Agency (EMA) will reviewMylan and Biocon‘s marketing authorisation application (MAA) for their proposed trastuzumab biosimilar, used to treat certain HER2-positive breast and gastric cancers.

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page